<DOC>
	<DOCNO>NCT00373243</DOCNO>
	<brief_summary>This study ass pharmacokinetics tolerability single dose GW406381 subject moderate hepatic impairment comparison match healthy volunteer . The hepatically impaired healthy group give single 20 mg oral dose GW406381 . Blood sample PK analysis collect pre-dose 72 hour post dose . Subjects house even dose 24 hour dose . A follow-up visit conduct 7 10 day last dose study drug .</brief_summary>
	<brief_title>A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Inclusion criterion : Healthy subject subject moderate hepatic impairment define ChildPugh score 79 Body weight less = 100 kg Body mass index ( BMI ) within range 19 32 32kg/m2 Exclusion criterion : Presence significant disease Use medication within 2 week prior dose , unless approve investigator GSK personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>hepatic impairment pharmacokinetics</keyword>
</DOC>